This is a news story, published by Yahoo, that relates primarily to J&J news.
For more vaccine development news, you can click here:
more vaccine development newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
experimental vaccine. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest efficacy news, experimental shot news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
vaccine candidateReuters
•Health
Health
84% Informative
The drugmaker said its decision was based on the recommendation of an independent committee.
Independent committee said vaccine candidate may not be sufficiently effective compared with a placebo.
No safety signals related to the experimental vaccine were identified, J&J said.
The study was testing the safety and efficacy of a single dose of the experimental shot, ExPEC9V.
VR Score
93
Informative language
98
Neutral language
89
Article tone
formal
Language
English
Language complexity
78
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links
Small business owner?
